BACKGROUND: Recent studies have shown that B7-H3, a recently identified B7 family member, plays a critical role in the development of asthma. OBJECTIVE: This study is to explore the expression of B7-H3 in children with asthma exacerbation. METHODS: Twenty-one Chinese children with asthma exacerbation as well as 18 nonasthmatic control Chinese children were enrolled. B7-H3 level and cytokines (interferon [IFN]-γ, interleukin [IL]-4, and IL-10) determination were performed by enzyme-linked immunosorbent assay (ELISA) technique. Meanwhile, clinical parameters including laboratory findings, forced expiratory volume in one second (FEV(1)) and fractional exhaled nitric oxide were obtained. RESULTS: Children with asthma exacerbation had significantly higher levels of B7-H3 than controls (4.46 ± 1.33 versus 3.42 ± 1.48 ng/mL; p = 0.027). Plasma IL-4 level was significantly higher in asthma exacerbation subjects than controls (157.98 ± 21.57 versus 121.92 ± 24.37 pg/mL; p < 0.0001), and IFN-γ level was significantly lower in asthma exacerbation subjects (292.73 ± 152.47 versus 421.78 ± 145.84 pg/mL; p = 0.0107). Level of B7-H3 in asthma exacerbation subjects with inhaled corticosteroid (ICS) treatment recently was significantly lower than subjects without ICS treatment (t = 2.706; p = 0.0136). Additionally, levels of B7-H3 decreased remarkably after prednisone treatment. Level of sB7-H3 in asthma exacerbation subjects was inversely correlated with level of IFN-γ (r(p) = -0.605; p = 0.005) after adjustment. CONCLUSION: B7-H3 may play an important role in asthma exacerbation and was a useful clinical biomarker to evaluate asthma exacerbation.
BACKGROUND: Recent studies have shown that B7-H3, a recently identified B7 family member, plays a critical role in the development of asthma. OBJECTIVE: This study is to explore the expression of B7-H3 in children with asthma exacerbation. METHODS: Twenty-one Chinese children with asthma exacerbation as well as 18 nonasthmatic control Chinese children were enrolled. B7-H3 level and cytokines (interferon [IFN]-γ, interleukin [IL]-4, and IL-10) determination were performed by enzyme-linked immunosorbent assay (ELISA) technique. Meanwhile, clinical parameters including laboratory findings, forced expiratory volume in one second (FEV(1)) and fractional exhaled nitric oxide were obtained. RESULTS:Children with asthma exacerbation had significantly higher levels of B7-H3 than controls (4.46 ± 1.33 versus 3.42 ± 1.48 ng/mL; p = 0.027). Plasma IL-4 level was significantly higher in asthma exacerbation subjects than controls (157.98 ± 21.57 versus 121.92 ± 24.37 pg/mL; p < 0.0001), and IFN-γ level was significantly lower in asthma exacerbation subjects (292.73 ± 152.47 versus 421.78 ± 145.84 pg/mL; p = 0.0107). Level of B7-H3 in asthma exacerbation subjects with inhaled corticosteroid (ICS) treatment recently was significantly lower than subjects without ICS treatment (t = 2.706; p = 0.0136). Additionally, levels of B7-H3 decreased remarkably after prednisone treatment. Level of sB7-H3 in asthma exacerbation subjects was inversely correlated with level of IFN-γ (r(p) = -0.605; p = 0.005) after adjustment. CONCLUSION:B7-H3 may play an important role in asthma exacerbation and was a useful clinical biomarker to evaluate asthma exacerbation.